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Abstract
The first extensively drug resistant (XDR) Neisseria gonorrhoeae strain with high resistance to the extended-spectrum
cephalosporin ceftriaxone was identified in 2009 in Japan, but no other strain with this antimicrobial-resistance profile has been
reported since. However, surveillance to date has been based on phenotypic methods and sequence typing, not genome
sequencing. Therefore, little is known about the local population structure at the genomic level, and how resistance
determinants and lineages are distributed and evolve. We analysed the whole-genome sequence data and the antimicrobial-
susceptibility testing results of 204 strains sampled in a region where the first XDR ceftriaxone-resistant N. gonorrhoeae was
isolated, complemented with 67 additional genomes from other time frames and locations within Japan. Strains resistant to
ceftriaxone were not found, but we discovered a sequence type (ST)7363 sub-lineage susceptible to ceftriaxone and cefixime in
which the mosaic penA allele responsible for reduced susceptibility had reverted to a susceptible allele by recombination.
Approximately 85% of isolates showed resistance to fluoroquinolones (ciprofloxacin) explained by linked amino acid
substitutions at positions 91 and 95 of GyrA with 99% sensitivity and 100% specificity. Approximately 10% showed resistance
to macrolides (azithromycin), for which genetic determinants are less clear. Furthermore, we revealed different evolutionary
paths of the two major lineages: single acquisition of penA X in the ST7363-associated lineage, followed by multiple independent
acquisitions of the penA X and XXXIV in the ST1901-associated lineage. Our study provides a detailed picture of the distribution
of resistance determinants and disentangles the evolution of the two major lineages spreading worldwide.
DATA SUMMARY
1. Genome read data for all samples has been deposited into
the DNA Data Bank of Japan (DDBJ) and mirrored at the
National Center for Biotechnology Information (NCBI) under
BioProject accession numbers PRJDB6496 and PRJDB6504
(www.ncbi.nlm.nih.gov/bioproject/?term=PRJDB6496 and
www.ncbi.nlm.nih.gov/bioproject/?term=PRJDB6504)
2. Metadata of all samples (such as individual sample acces-
sion numbers, information of multilocus sequence typing,
geographical region, minimum inhibitory concentration
values and genetic polymorphisms of each strain) is sum-
marized in Tables S1 and S2 (available with the online ver-
sion of this article).
INTRODUCTION
Antimicrobial resistance (AMR) is one of the greatest
threats to human health and needs to be monitored and
addressed at a global level [1, 2]. The number of infections
caused by multidrug-resistant bacteria is increasing globally
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at a concerning rate [1]. Among bacterial pathogens that
can be resistant to antimicrobial drugs, Neisseria gonor-
rhoeae is ranked as one of the three most ‘urgent’ threats by
the CDC [3]. Gonorrhoea is one of the most common bacte-
rial sexually transmitted infections worldwide and causes
substantial morbidity and economic loss [4–6].
The first extensively drug resistant (XDR) gonorrhoea strain
[7, 8] was H041, isolated in 2009 in Kyoto, Japan [9], fol-
lowed by XDR strain F89 in Quimper, France [10]. XDR
strains are defined as being resistant to two or more of the
antibiotic classes generally recommended for the treatment
of gonorrhoea, and three or more less frequently prescribed
classes [7]. H041 and F89 showed comparatively high mini-
mum inhibitory concentration (MIC) values of 2 and 1 µg
ml 1, respectively [9, 10], to the antimicrobial drug ceftriax-
one, which is currently the last remaining option for empiri-
cal first-line monotherapy in most countries. H041 and F89
were also resistant to fluoroquinolones and macrolides,
including azithromycin, which together with ceftriaxone
forms the dual therapy currently recommended for the
treatment of gonorrhoea in international and national
guidelines [6, 11, 12].
Large-scale whole-genome sequencing of bacterial isolates
is quickly becoming the gold standard method for under-
standing AMR determinants and conducting surveillance
of their prevalence and spread [13–17]. A recent genomic
epidemiology study [18] analysed the genome sequences
of 1102 gonococcal isolates sampled from across the USA
over a 14 year period (2000–2013). The MIC values of
extended-spectrum cephalosporins (ESCs, including cefix-
ime and ceftriaxone), macrolides (azithromycin) and fluo-
roquinolones (ciprofloxacin) were examined to evaluate
the extent to which known genetic resistance determi-
nants can explain the observed phenotypic resistance
[18]. Notably, this study reported the existence of
unknown mechanisms of resistance to ceftriaxone and
azithromycin, highlighting the importance of phenotypic
surveillance.
However, such a genomic epidemiology study has not yet
been conducted in the geographical regions where the
first XDR strains were isolated. Although no other XDR
strain has been subsequently reported in the local com-
munities of Kyoto and Osaka, or elsewhere nationwide
[19], Japan remains a region of global health concern for
the emergence of XDR gonorrhoea bacteria due to high
resistance rates to cefixime, azithromycin and ciprofloxa-
cin [20]. It is, therefore, important to perform genomic
surveillance to study the population structure of gonor-
rhoea bacteria in Japan at the genomic level, the presence
of any lineage or sub-lineage that exhibits unusual pat-
terns of reduced susceptibility to antimicrobials, and the
evolution of such lineages. Additionally, the distribution
of genetic resistance determinants and the extent to
which these determinants can explain the observed phe-
notypic resistance in Japan remains unknown.
In this study, we explored these issues by analysing the
whole-genome sequences and the antimicrobial-susceptibil-
ity testing results of 204 gonococcal strains sampled through
genomic surveillance in the Japanese prefectures of Kyoto
and Osaka (coloured in red on the map in Fig. S1) in 2015,
as well as those of the H041 strain, as a reference. To pro-
vide context to our findings, we also analysed the whole-
genome sequences of 67 additional gonococcal strains iso-
lated from other time frames and locations within Japan.
Our study revealed a detailed picture of the distribution of
antimicrobial-resistance determinants and their relationship
with phenotypic antimicrobial susceptibility and the evolu-
tion of two major lineages.
METHODS
Isolates, antimicrobial susceptibility testing and
DNA sequencing
Four outpatient clinics located in different areas (two in
Kyoto and two in Osaka, Japan) provided specimens from
all male patients who showed symptoms of gonorrhoea to
the National Institute of Infectious Diseases (NIID), Tokyo,
for the isolation of N. gonorrhoeae. Approximately 60% of
the specimens were culture-positive for N. gonorrhoeae (see
[19] for details of the procedure), all of which were subject
to antimicrobial-susceptibility testing and genome sequenc-
ing as follows: in 2015, a total of 204N. gonorrhoeae isolates
(1 per patient, from a total of 18 and 186 patients in
Kyoto and Osaka, respectively) were obtained (Table S1),
IMPACT STATEMENT
Antimicrobial resistance (AMR) is now recognized as one
of the greatest threats to human health, and resistance
in Neisseria gonorrhoeae is classified as one of the most
urgent. The first extensively drug resistant strain with
high resistance to first-line antimicrobial drugs was
identified in 2009 in Japan, but subsequent surveillance
has not been based on genome sequences. In this study,
we conducted genomic surveillance and examined the
AMR of >200 strains, as well as 67 additional strains
from other time frames and locations within Japan. We
discovered an interesting group of strains that had lost
AMR due to the incorporation of DNA fragments from
susceptible strains into a gene responsible for resis-
tance. We also revealed the prevalence of strains resis-
tant to each clinically important antimicrobial drug and
investigated to what extent genetic resistance determi-
nants can explain the observed phenotypic resistance.
Furthermore, we revealed that the two major lineages
spreading worldwide took very different evolutionary
paths. Our study has major microbiological and clinical
importance for the development of diagnostics and AMR
tests, as well as for elucidating the origin and evolution
of the resistant lineages that likely originated in Japan.
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corresponding to approximately 23% of male gonorrhoea
patients reported by 65 sentinel clinics in Osaka in 2015,
according to a public report of the Osaka prefecture.
Although there could be potential biases in the patient pop-
ulation that is served by these clinics (e.g. socioeconomic
biases, differences in the proportion of the population classi-
fied as men who have sex with men), this is the largest
sampling of N. gonorrhoeae isolates conducted in the prefec-
tures. The MICs (µg ml 1) of ceftriaxone, cefixime, cipro-
floxacin and azithromycin were determined using the Etest
method (bioMerieux) for each drug separately, according to
the manufacturer’s instructions (Table S1). In order to
define susceptible/intermediate/resistant phenotypes, we
used the following MIC cut-offs according to the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST; www.eucast.org/clinical_breakpoints): suscepti-
bility 0.125 µgml 1 and resistance >0.125 µgml 1 for cef-
triaxone and cefixime; susceptibility 0.25 µgml 1 and
resistance >0.5 µgml 1 for azithromycin; and susceptibility
0.03 µgml 1 and resistance >0.06 µgml 1 for ciprofloxa-
cin. Genomic DNA of each isolate was extracted with a
MagNA Pure LC DNA isolation kit on a MagNA pure LC
instrument (Roche Diagnostics), and was used for Nextera
XT library construction and genome sequencing with an
Illumina MiSeq 2300 bp paired-end run protocol. The raw
read data were deposited in the DNA Data Bank of Japan
(DDBJ) and mirrored at the National Center for Biotechnol-
ogy Information (NCBI) under BioProject accession num-
ber PRJDB6496. We measured the MICs using the Etest
three times for the following strains for which the genotypes
and phenotypes were initially discordant, and used median
of MICs: FC488 (azithromycin), FC498 (ceftriaxone and
cefixime), FC532 (ciprofloxacin) and FC524 (ciprofloxacin).
Construction of the clonal phylogeny at the species
level
The Illumina read data (300 bp paired-end reads) of each
isolate were used for de novo assembly by A5-MiSeq with
the default settings to produce contigs without scaffolding
[21]. The number of contigs, N50 and raw coverage of each
isolate are summarized in Table S1. We combined the data
with the complete genome sequence of the H041 strain,
which was recently determined using PacBio sequencing
and named ‘WHO X’ [22]. Multilocus sequence typing
(MLST) of the strains was conducted by exact string match-
ing of the allelic sequences defined in PubMLST (www.
pubmlst.org/neisseria) [23] to the contigs. If there was no
exact string match, we conducted a BLASTN search of the
contigs of the strain against the allelic sequences, and
checked the top hit allele and its alignment. If the top hit
had only a single nucleotide change, we assigned it to its
closest sequence type (ST) and marked it with an asterisk
(in the ST column in Table S1). We annotated each genome
using Prokka [24]. As in a previous study [25], for single
nucleotide polymorphism (SNP) calling and evolutionary
analyses, we first conducted pairwise genome alignment
between H041 (WHO X) and one of the 204 strains using
progressiveMauve [26], rather than mapping their reads to
the H041 (WHO X) reference genome. progressiveMauve
enables the construction of positional homology alignments
even for genomes with variable gene content and rearrange-
ment. We then combined the alignments into a multiple
whole-genome alignment, in which each position corre-
sponded to that of the H041 (WHO X) genome. In the
whole-genome alignment, we identified 24 455 core biallelic
SNPs, which is comparable to the 34 959 core SNPs reported
previously using a broader sampling: 242 gonococcal iso-
lates collected by the CDC’s Gonococcal Isolate Surveillance
Project (GISP) from 28 cities in the USA in 2009–2010,
which were included in a recent genomic epidemiology
study [18] and have also been analysed separately [27]. For
validation, we also constructed another whole-genome
alignment using a pipeline [28] that similarly conducts pair-
wise genome alignment between a reference genome and
one of the other genomes using MUMmer [29]. We con-
firmed that the genome contained a very similar number of
core biallelic SNPs (22 239), in which 21 402 SNPs were
shared between the two genome alignments. We con-
structed a maximum-likelihood tree using PhyML [30]
from the former genome alignment containing the 24 186
core SNPs. We used the following parameters that indicate
the GTR +G4model of DNA substitution with estimation
of the shape parameter of the gamma distribution by maxi-
mizing the likelihood: -m GTR -c 4 -a e. Using this as a
starting tree, we constructed a clonal phylogeny at the spe-
cies level with corrected branch lengths to account for
homologous recombination using ClonalFrameML [31].
We first applied the standard model, and then applied the
extended model using parameter estimates of the standard
model: embranch_dispersion=0.1, kappa (relative rate of
transitions vs transversions in substitution model)=3.148 as
inferred by PhyML, initial value of R= (ratio of rates of
recombination and mutation)=0.534, 1=d (inverse mean
DNA import length)=0.012, and n (mean divergence of
imported DNA)=0.094. The extended model allows for dif-
ferent recombination parameters to be inferred on different
branches of the clonal phylogeny. Neither the maximum-
likelihood starting tree, nor the clonal phylogeny, were
rooted using an outgroup outside the species, and we
showed the clonal phylogeny as mid-point rooted. We used
the alignment sites that were present in at least 70% of
strains in order to focus on core and fairly conserved sites
with a missing frequency 30%. Furthermore, we con-
firmed that applying a cut-off of 90% did not cause any visi-
ble change to the clonal phylogeny: the change in branch
length was on average 1.610 6 nucleotide substitutions
per site
Analysis of genetic AMR determinants
For ESC (cefixime and ceftriaxone) resistance determinants,
we extracted the nucleotide sequences of penA, which enco-
des the ESC-target penicillin-binding protein 2 (PBP2), by
BLASTN searching the locus of the H041 (WHO X) strain
against each of the other genomes. We used a BLASTN match
of 70% identity over 50% of the locus length as the cri-
teria for positive detection of the gene [32]. These criteria
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can extract both the mosaic and other penA alleles accord-
ing to the sequence identities reported in previous studies
[33, 34]. We constructed a neighbour-joining unrooted tree
of penA using a Kimura two-parameter model implemented
in MEGA 6 [35]. We used the entire coding sequence of penA
in order to classify penA alleles according to their entire
nucleotide sequences on the tree, which could then be com-
pared to the clonal phylogeny. We also identified specific
amino acid changes in PBP2 as well as PBP1 (encoded by
ponA), the outer-membrane porin PorB (encoded by penB)
and the MtrR efﬂux pump repressor, described in a recent
review [36], using their amino acid sequences aligned using
MAFFT v7.245 [37] and an in-house Perl script. We included
the ESC-susceptible reference strain FA1090 (GenBank
accession no. AE004969.1) in the alignment as a wild-type
amino acid reference sequence, and examined the associa-
tion between amino acid changes compared to the wild-type
and resistance to cefixime by Fisher’s exact test and multiple
testing correction via false discovery rate (FDR) [38] imple-
mented in R version 3.3.1. For fluoroquinolone (ciprofloxa-
cin) resistance determinants, we examined nonsynonymous
substitutions in gyrA and parC described in a recent review
[36]. For macrolide (azithromycin) resistance determinants,
we examined the two known primary mechanisms [39]:
adenosine deletion in the promoter region of mtrR [36], and
the A2059G and C2611T (Escherichia coli numbering)
mutations in the 23S rRNA gene [40]. We detected the pres-
ence or absence of these variants using ARIBA, which uses a
combined mapping/alignment and targeted local assembly
approach [41]. For macrolide (azithromycin) resistance
determinants, we also looked for the presence or absence of
erm genes [39] and the premature stop codon in the coding
sequence of mtrR (e.g. allele 367 defined in the PubMLST
Neisseria database [36, 42]), although none were found
among the 204 isolates and we excluded them from subse-
quent analyses. For plasmid-encoded resistance genes, we
also looked for the presence or absence of the blaTEM and
tetM genes [22, 36] using a BLASTN match of 70% identity
over 50% of the locus length. The presence or absence of
these genetic AMR determinants as well as the MICs of the
antimicrobial drugs for each strain were illustrated as heat-
maps using Phandango [43].
Inference of recombination in the susceptible
reverted penA allele
To confirm a recombination event (DNA import) from an
external source into the susceptible reversed penA allele of a
ST7363 sub-lineage, we constructed a subset of the multiple
whole-genome alignment described above for the strains in
the sub-lineage using H041 (WHO X) as a reference and the
FC489 strain carrying the penA X allele as an outgroup. We
selected strain FC489 as the outgroup because it was not
included in the sub-lineage but was its nearest neighbour:
sequence identity calculated from the whole-genome align-
ment excluding gapped sites between the outgroup strain
FC489 and strain KM304 in the sub-lineage is 99.95%,
equal to the lowest sequence identity between strains within
the sub-lineage. We then constructed a maximum-
likelihood tree using PhyML [30] and conducted a recombi-
nation analysis using Gubbins [44] by specifying the
maximum-likelihood tree as a starting tree and strain
FC489 as an outgroup. We then conducted a BLASTN search
of a recombined fragment overlapping penA in all 204N.
gonorrhoeae genomes in order to explore potential recombi-
nation sources.
Additional dataset of ST7363 and ST1901 strains
To compare our findings with those of other time points
and geographical regions, we selected the following isolates
and conducted genome sequencing of our isolate collection
(Table S2) according to the Illumina MiSeq procedure
described previously. First, we searched for and selected
40 ST7363 strains (out of 272 strains in total) isolated in
other geographical regions in 2015. Specifically, they were
isolated in Miyagi, Saitama, Aichi and Gifu, Japan (coloured
in blue on the map in Fig. S1). Second, we looked for
ST7363 strains with cefixime MICs<0.016 µgml 1 (the low-
est value measured by Etest as most likely indicating the
presence of a susceptible penA allele) isolated in Kyoto and
Osaka during 2011–2014 and selected six isolates that ful-
filled the criteria. Third, we looked for ST7363 and ST1901
strains that were isolated in the 1990s in a different geo-
graphical region to be used as outgroups for Bayesian evolu-
tionary analyses of the two lineages. From amongst such
historical strains isolated in Kanagawa, Japan (coloured in
orange on the map in Fig. S1), we selected 1 of 6 ST7363
strains isolated in 1996, whereas we selected all 20 ST1901
strains isolated from 1996 to 2000. We selected the larger
number of ST1901 strains based on preliminary analyses in
which we added a single or a few such strains for construc-
tion of time-resolved phylogeny of ST1901 (next section)
but did not obtain an interpretable phylogeny carrying a
particular root. The MICs (µg ml 1) of ceftriaxone and
cefixime of the historical strains isolated in Kanagawa were
determined by agar-dilution at the Kanagawa Prefectural
Institute of Public Health. The raw read data were deposited
in the DDBJ and mirrored at the NCBI under BioProject
accession number PRJDB6504.
Construction of time-resolved phylogeny of the two
major lineages
We conducted pairwise genome alignment between H041
(WHO X) and each of the additional ST7363 and ST1901
strains using the same methods as above. We then com-
bined them with a subset of the multiple whole-genome
alignment described above for the strains in the ST7363-
and ST1901-associated lineages, separately. From the
whole-genome alignment of each lineage, we constructed a
maximum-likelihood tree using PhyML with the same
model and parameters described above. In order to demon-
strate that the data of the lineages have temporal signal, we
plotted the sampling year versus root-to-tips correlation
using TempEst [45] (Fig. S2). We also performed the date
randomization tests using the ‘roottotip’ function of Bact-
Dating [46] and confirmed that the temporal signal is sig-
nificant in both ST7363- and ST1901-associated lineages
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(P=0.018 and P <10 5). Using the maximum-likelihood tree
as a starting tree, we applied the standard model of Clonal-
FrameML to each linage and inferred individual recombina-
tion events imported from outside the lineage. We excluded
all recombined sequences from the whole-genome align-
ment, and then extracted 1079 and 3255 core biallelic SNPs
for the ST7363- and ST1901-associated lineages. We then
constructed a time-resolved phylogeny using the SNPs and
BEAST version 1.10.0 [47], for which we specified the GTR
+G4model of DNA substitution with estimation of the
shape parameter of the gamma distribution. We estimated
and compared log marginal likelihood of the constant popu-
lation size model and the exponential population growth
model using generalized stepping-stone sampling (GSS)
[48]. BEAST was run for 100million Markov chain Monte
Carlo (MCMC) iterations, followed by 100 path steps of
1million iterations for GSS, with samples taken every 1000
iterations. We used Tracer v1.7 [49] to check that the effec-
tive sample size (ESS) of all parameters exceeded 500 and
that runs had converged. We chose the simpler constant
population size model because it showed a larger log mar-
ginal likelihood (Bayes Factor >3.5) for both the ST7363-
and ST1901-associated lineages. We also tried to apply the
relaxed clock rate model coupled with the constant popula-
tion size model, but did not choose it because it yielded ESS
<200 for several parameters. The time-resolved phylogeny
was automatically rooted by BEAST using outgroup strains in
each lineage. We prepared the input xml files based on those
exported from BEAUti version 1.8.4 rather than version
1.10.0, because the latter caused runtime errors in GSS, and
made them publicly available at https://figshare.com/s/
1f12166596282b841e05. A maximum clade credibility tree
was generated for ST7363 and ST1901 after discarding 10%
as burn-in by using TreeAnnotator (part of the BEAST
package). All nodes and branches with posterior support
values with  0.9 were marked using FigTree version 1.4.3.
RESULTS
Analysis of susceptibility to the ESCs, examination
of penA alleles and the discovery of a novel sub-
lineage
For the 204 strains sampled in the Japanese prefectures of
Kyoto and Osaka in 2015 (Table S1) and reference strain
H041 (WHO X), a clonal phylogeny with branch lengths
corrected to account for homologous recombination was
inferred using ClonalFrameML (Fig. 1). The ratio of rates of
recombination and mutation was estimated to be 0.56,
whereas the ratio of the number of substitutions predicted
to have been imported through recombination and point
mutation was 5.94, a relatively high value among bacterial
species [50].
The two major STs, ST7363 (36 isolates) and ST1901 (33
isolates), and their variants are highlighted in the first col-
umn of Fig. 1. In total, 20 STs were found, and their fre-
quency distribution is shown in Fig. S3. Susceptible/
resistant categories according to the EUCAST MIC
breakpoint (susceptibility 0.125 µgml 1 and resistance
>0.125 µgml 1) of ESCs (cefixime and ceftriaxone) are col-
oured in the second and third columns in Fig. 1. The pres-
ence or absence of any mosaic penA allele (specifically,
FC428-type [34], H041-type [9], X and its variants [19], and
XXXIV and its variant [19] in this paper) is indicated in the
fourth column. The penA alleles have been designated
according to amino acid sequences encoded by the whole
gene, and alleles such as X and XXXIV were termed ‘mosaic’
because the second half of their DNA sequences appear to
have been imported from other Neisseria spp. that are natu-
rally resistant to ESCs through homologous recombination
events [51]. The presence or absence of a specific penA allele
is indicated in the 5th–11th columns. The 11th column cor-
responds to penA allele V, which is not one of the mosaic
alleles but confers susceptibility to ESCs. The most frequent
mosaic penA alleles were X and its variants, whereas a previ-
ous study in the USA focused on penA XXXIV and its var-
iants, as they were predominant in the sampled time frame
(2005–2013) [18].
The MIC values of cefixime and ceftriaxone were signifi-
cantly higher in the presence of the mosaic penA alleles
(Figs S4 and S5, P<10 15, Wilcoxon’s rank-sum test). How-
ever, aside from H041 (WHO X), only three strains (FC498,
FC460 and FC428) satisfied the ceftriaxone-resistance cut-
off (MIC>0.125 µgml 1), all of which carried FC428-type
penA [34]. There were 51 strains satisfying the cefixime-
resistance cut-off (MIC>0.125 µgml 1) that were associated
with the mosaic penA with 92% sensitivity and 62% speci-
ficity (Fig. S5).
We also examined the specific amino acid changes of PBP2
(encoded by penA), as well as PBP1 (encoded by ponA), the
outer-membrane porin PorB (encoded by penB) and the
MtrR efﬂux pump repressor. Among 217 sites that had
amino acid changes, 51 sites showed a significant associa-
tion with cefixime resistance (PFDR <10
 5, Fisher’s exact
test), consisting of 48 sites in PBP2 and 3 sites in PorB. The
most significant association (P=310 12, PFDR=510
 11)
was found in PBP2 N513Y and G546S, and their sensitivity
(92%) and specificity (62%) were the same as those of
mosaic penA. These findings are expected since the amino
acids are located in the C-terminal domain of PBP2, charac-
teristic of mosaic penA [9]. Among the 48 significant sites
in PBP2, 42 were located in the C-terminal domain (sites
279, 288, 291, 312, 316, 323, 326, 328, 329, 330, 331, 332,
335, 341, 342, 343, 345, 353, 374, 376, 377, 378, 386, 389,
407, 412, 413, 438, 444, 448, 458, 462, 463, 465, 469, 470,
473, 481, 513, 517, 542 and 546), whereas 6 were in the N-
terminal domain (160, 173, 202, 203, 204 and 214). Regard-
ing PorB, the presence or absence of the amino acid changes
in the three significant sites (120, 121 and 210) is indicated
in the 12th–14th columns in Fig. 1. The amino acid changes
in PorB were significantly associated with mosaic penA
(P<510 15), suggesting an epistatic interaction between
them >270 kb apart in the chromosome.
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Fig. 3. Time-resolved phylogeny and penA polymorphisms. All nodes and branches with posterior support values with 0.9 are col-
oured in purple. The cyan branches indicate acquisition of penA X or XXXIV, whereas the yellow branch indicates loss of penA X by
recombination. The cyan, yellow and green circles indicate nodes with 95% HPD described in the text. Heatmap: column 1, ST: the ST
of the genomes harbouring the penA alleles. The two major STs (ST7363 and ST1901), single-locus variants of the former (ST7356,
ST1932) and the latter (ST7360 and ST1579), and a new ST (double-locus variant of ST1901) are coloured. Columns 2–3: susceptible/
resistant (S/R) categories according to the EUCAST MIC breakpoint of cefixime (CFM) and ceftriaxone (CRO). The presence or absence
Yahara et al., Microbial Genomics 2018;4
8
Downloaded from www.microbiologyresearch.org by
IP:  137.205.202.233
On: Tue, 02 Oct 2018 15:47:15
ST7363 (coloured blue in the ST column in Fig. 1) formed a
single lineage in the phylogeny, which contained only
ST7363 and its single locus variants (ST7356 or ST1932).
Interestingly, however, the lineage was divided into two
sub-lineages: one included the H041 (WHO X) strain and
contained mosaic penA alleles (H041-type or X), while the
other (blue rectangle in the any mosaic column in Fig. 1)
did not have any mosaic penA alleles and was susceptible to
cefixime and ceftriaxone.
A neighbour-joining tree of penA nucleotide sequences is
shown in Fig. 2. The mosaic and other penA alleles were
completely separated into two clusters (upper and lower) in
the tree. The mosaic penA alleles were carried by the major-
ity of the ST1901 and ST7363 strains; exceptions were the
susceptible sub-lineage of ST7363 (indicated by the blue
rectangle in the any mosaic column in Fig. 2) and the sub-
lineage of ST1901 that carried the penA V allele. Examina-
tion of the susceptible penA allele in the sub-lineage of
ST7363 revealed that the first half of the sequence was iden-
tical to that of the mosaic penA X or H041 alleles, but that
the second half was recombined with that of the penA V
allele (inset in Fig. 2).
The susceptible sub-lineage of ST7363 seems to have
evolved from its ancestor, which carried penA X (Fig. 1).
Genome sequences within the sub-lineage are very closely
related (99.97% sequence identity). Inference of individ-
ual recombination events that imported DNA fragments
from external sources into the sub-lineage using Gubbins
revealed a recombined fragment spanning approximately
3.3 kb from the second half of penA to the 2.5 kb down-
stream intergenic region. A BLASTN search of the recom-
bined fragment in the genomic population of the 204 strains
confirmed that a strain carrying penA V was a donor for
recombination, evident because the whole fragment had
>99.98% sequence identity with strains carrying penA V.
The next most closely related BLASTN hit was 99.34%, found
in strain KM311 (lower in Fig. 1, outside the ST7363- and
ST1901-associated linages) that encodes a 2 amino acid var-
iant of penA V. We do not term this allele, derived from
penA X and penA V, mosaic because it indicates an allele
that can confer resistance to ESCs, which is not the case for
this allele.
Metadata of each isolate, such as MLST information
(including allele numbers of the seven loci), MIC values and
genetic polymorphisms are summarized in Table S1. Amino
acid sequences of the penA alleles in Fig. 2, penA V variants
in Fig. 3 and the ESC-susceptible reference strain FA1090
are summarized as a supplementary FASTA file (https://fig-
share.com/articles/penA_sequences/6756845).
Quinolone resistance
Approximately 85% of the strains showed resistance to flu-
oroquinolones (ciprofloxacin MIC >0.06 µgml 1 according
to EUCAST). In N. gonorrhoeae, quinolone resistance has
been attributed to nonsynonymous substitutions in specific
regions of gyrA and parC, namely GyrA amino acid posi-
tions 91 and 95, and ParC position 87, and less frequently
ParC positions 86 and 88 [18]. Susceptible/resistant catego-
ries of ciprofloxacin and the presence of these substitutions
are summarized in the 15th–20th columns in Fig. 1. The
resistance is explained by completely linked amino acid sub-
stitutions at positions 91 and 95 of GyrA with 99% sensitiv-
ity and 100% specificity. Only two of the resistance strains
did not have the linked amino acid substitutions (Fig. S6).
Among the parC polymorphisms, ParC S87IR was the most
frequent. Most strains carried either ParC D86N or ParC
S87IR, while no strain carried both. Additionally, all strains
carrying parC S88P also had parC S87IR. Strains without
the amino acid substitutions in GyrA formed two groups in
the clonal phylogeny (upper and bottom in Fig. 1). They
had none of the substitutions attributed to quinolone resis-
tance in GyrA or ParC.
Azithromycin resistance
Approximately 10% of the strains showed resistance to azi-
thromycin (MIC >0.5 µgml 1 according to EUCAST). The
resistance has previously been attributed to mutations in the
23S rRNA gene or in the mtrR (a repressor of efflux pump)
locus or its promoters [18, 40]. In our dataset, the resistance
is explained by an adenosine deletion in the promoter
region of mtrR, with 95% sensitivity, but only 52% specific-
ity (Fig. S7). Susceptible/intermediate/resistant categories
and the presence of the deletion as well as of the mutations
(C2611T or A2059G) in the 23S rRNA gene are summa-
rized on the right-hand side of Fig. 1. All ST1901 strains
had the deletion (Fig. 1). In contrast, the deletion in the pro-
moter region of mtrR was not found in any ST7363 strains
except for H041 (WHO X) (blue rectangle in the mtrR pro-
moter A deletion column in Fig. 1). Further examination of
another dataset of 40 ST7363 strains isolated in 2015 in
other geographical regions (Miyagi, Saitama, Aichi and
Gifu, Japan, coloured in blue in Fig. S1) (Table S2) revealed
an almost perfectly consistent result, with 93% of the strains
not harbouring the adenosine deletion in the mtrR
promoter.
of genetic features is shown in columns 4–9 as marked: grey indicates absence, other colours indicate presence. Column 4: any
mosaic penA allele. Columns 5–7: penA H041-type, X and variants, and XXXIV and variants. Column 8: penA V. Column 9: variants of
penA V: light and dark yellow-green indicate 4 and 5 amino acid variants, respectively. (a) ST7363 and its single locus variants. The
blue rectangle indicates the notable sub-lineage sharing the susceptible penA allele reverted by recombination. (b) ST1901-associated
lineage. The yellow-green arrow indicates an exceptional strain isolated in 2015 that contained the ancestral susceptible penA V
variant.
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The A2059G and C2611T mutations in the 23S rRNA gene
were found only in a single strain (FC488), which showed
high-level resistance, with an azithromycin MIC of >256 µg
ml 1, and the three strains with MIC values of 16, 8 and 1
[39] (Table S1). The three showing an azithromycin MIC
>1 were the only strains that carried one of the mutations in
the 23S rRNA gene. To account for the presence of four
copies of the gene in the N. gonorrhoeae genome, we exam-
ined the depth of reads mapped to each nucleotide at the
two positions in the four strains. In the strain carrying
A2059G, all reads covering that position were mapped to
the resistant nucleotide. In two out of the three strains car-
rying C2611T with MIC values of 8 and 16, all or almost all
(>99%) reads covering that position were mapped to the
resistant nucleotide, whereas only 60% of reads did so in
the remaining strain that had a MIC value of 1.
Plasmid-encoded resistance
The blaTEM gene, which confers resistance to b-lactams, was
not found in either ST7363- or ST1901-associated clades.
Rather, it was found in ST7827, ST1903 (upper in Fig. 1),
ST1599 and ST13476 (bottom in Fig. 1). Similarly, tetM,
which confers resistance to tetracycline, was found only in
ST1599 (upper in Fig. 1), ST10899, ST1597 and ST13476
(lower in Fig. 1). Only two strains (FC493 of ST1599 and
KM311 of ST13476) were found to carry both the genes,
each of which was originally located in different plasmids
[22, 36]. Although it is challenging to reconstruct plasmids
themselves from the Illumina short-read data, the results
show that the plasmid-encoded resistance in this geographi-
cal region is confined to the minor STs that consist of the
two lineages outside ST7363 and ST1901.
Evolution of ST7363- and ST1901-associated
lineages and penA alleles
For further examination of the susceptible penA allele
reverted by recombination and the sub-lineage in ST7363,
we investigated penA alleles of six historical ST7363 strains
with cefixime MICs <0.016 µgml 1 (the lowest value mea-
sured by Etest, most likely indicating presence of a suscepti-
ble penA allele) isolated in Kyoto and Osaka during 2011–
2014 (Table S2). We have confirmed that all strains carried
the susceptible reverted allele. Next, we constructed a time-
resolved phylogeny of the ST7363-associated lineage
(Fig. 3a) by adding one historical ST7363 strain isolated in
Kanagawa (coloured in orange in Fig. S1) in 1996 in addi-
tion to the six historical strains. The phylogeny clearly
shows that penA evolved from an ancestral susceptible allele
(4 amino acid variant of penA V) to penA X by a single
event (on a cyan branch in Fig. 3a) prior to 1998 [at the
node marked by a cyan circle in with 95% highest posterior
density (HPD) (1984.0–1997.8)]. The susceptible allele
reverted by recombination between penA X and penA V,
emerged by a single event (on a yellow branch in Fig. 3a)
prior to 2007 [at the node marked by a yellow circle in with
95% HPD (2001.2–2006.5)], and have been inherited and
shared among the sub-lineage and ancestors (blue rectangle
in Fig. 3a).
By contrast, ST1901 (coloured in orange in ST column in
Fig. 1) and its variants (single locus variants ST7360 and
ST1579 and a new ST, which is a double locus variant of
ST1901, coloured in light orange) formed a large lineage in
which ST1901 seemed to be paraphyletic, corresponding to
different penA alleles: X and its variants, XXXIV and its var-
iant, and V. In other words, the two sub-lineages carrying
the two types of mosaic penA alleles (X and XXXIV) are
phylogenetically distinct at the core genome level even in
this single geographical region. In order to understand how
they evolved, we constructed a time-resolved phylogeny of
the ST1901-associated lineage (Fig. 3b) by adding 20 histor-
ical ST1901 strains isolated in Kanagawa from 1996 to 2000.
The time-resolved phylogeny shows penA evolved from the
ancestral susceptible allele (a 4 amino acid variant of penA
V) as that of ST7363. Before the 1990s [i.e. at the node
marked by a green circle in Fig. 3(b) with 95% HPD
(1985.8–1989.0)], the ancestral allele was replaced by penA
V. After that, the mosaic penA X and XXXIV were likely to
have been separately acquired by their ancestors. In particu-
lar, penA X was likely to have been acquired twice on differ-
ent branches. Meanwhile, the sub-lineages of ST1901
carrying penA V were not completely replaced by those car-
rying penA X or XXXIV, but were maintained at low fre-
quency. Exceptionally, a singleton strain KM309 isolated in
Osaka in 2015 (yellow-green arrow in Fig. 3b, next to the
strains carrying penA X) carried the ancestral susceptible
penA (the 4 amino acid variant of penA V), which is likely
to have been reverted from penA X by recombination.
DISCUSSION
We conducted genomic surveillance in 2015 and a genomic
epidemiology study in a Japanese region where the first iso-
late of XDR ceftriaxone-resistant N. gonorrhoeae was identi-
fied. We confirmed that no additional XDR ceftriaxone-
resistant strains have emerged thus far, similar to other
regions in the world, potentially indicating that XDR strains
suffer from decreased biological fitness [52]. Mutations in
penA that confer resistance to ESCs are predicted to have a
negative impact on gonococcal fitness, given that this gene
functions in cell-wall biosynthesis [53].
Despite finding no additional XDR ceftriaxone-resistant
strains, we discovered a sub-lineage of ST7363 that had lost
the mosaic penA allele responsible for reduced susceptibility
to ESCs, and instead maintained a susceptible penA allele
that had been reversed by recombination. We also discov-
ered that none of the ST7363 strains, except for H041
(WHO X), harboured the adenosine deletion in the mtrR
promoter, which predicts azithromycin resistance with 95%
sensitivity (but only 52% specificity). A recent study exam-
ining 75 azithromycin-resistant N. gonorrhoeae isolates cul-
tured from 2009 to 2014 in 17 European countries did not
find an ST7363 isolate without the deletion [40]. Although
it has been suggested that most AMR mechanisms in N.
gonorrhoeae do not appear to confer a significant fitness
cost [52], these findings suggest that loss of resistance deter-
minants could be advantageous for gonococci, depending
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upon environmental conditions. Otherwise, the loss of resis-
tance could be due to sufficient recombination and a lack of
selection for resistance. The availability of regional informa-
tion regarding antimicrobial usage would be helpful to for-
mally quantify the fitness costs and benefits of resistance
[54], although no such data are currently accessible.
A similar re-emergence of antimicrobial susceptibility in a
resistant lineage was recently reported in N. gonorrhoeae in
the USA [17, 18], as well as in Staphylococcus aureus in the
UK [55]. The USA study reported that the strains suscepti-
ble to ESCs appear to have undergone a recombination
event that replaced the resistant mosaic penA XXXIV allele
with the susceptible mosaic penA XXXVIII. Similarly, we
were able to reconstruct the evolutionary history of the sub-
lineage as follows: a DNA fragment was imported from out-
side the lineage into the second half of the penA locus,
resulting in creation of the susceptible reverted allele; the
donor of recombination was identified as penA V. Whilst
previous studies have not examined MLST information, we
carefully examined the relationships between ST and sub-
lineage.
We found that most (approximately 85%) of the isolates in
the Japanese region (Kyoto and Osaka) were quinolone
resistant. This finding is consistent with previous observa-
tions that most quinolone-resistance mutations in N. gonor-
rhoeae are associated with little to no ﬁtness cost [18].
Otherwise, there is also a possibility that the strains harbour
compensatory mutations to recover fitness costs, as recently
reported for mosaic penA alleles [53]. Recent studies in
China [56, 57] showed that the frequency of quinolone-
resistant strains was almost 100% in 2008, 2010 and 2012–
13. These observations could be due to heavy quinolone use
in these countries. In addition, the simultaneous amino acid
substitutions in GyrA 91 and 95 could confer an in vivo fit-
ness benefit to the wild-type, as has been demonstrated in a
competition experiment [58].
Our genomic surveillance revealed a detailed picture of the
distribution of AMR determinants and their relation to phe-
notypic antimicrobial susceptibility in a region of public
health concern. The results particularly suggest that the
simultaneous amino acid substitutions in GyrA 91 and 95
could be a marker of resistance to fluoroquinolones in this
geographical region, in addition to other geographical
regions such as the USA [17], Russia [59] and India [60]
where a strong association between the substitutions in
GyrA and fluoroquinolone resistance has been reported.
The marker can be utilized for point-of-care diagnostic and
AMR tests (POC-AMR), the importance of which has been
shown for enabling prompt diagnosis and individualized
treatment, and helping to combat the spread of AMR [61,
62]. Such tests are already in development: for example,
nucleic acid amplification tests (NAATs) detect markers in
gyrA directly from clinical samples [63]. Our study revealed
that there was no single marker capable of discriminating
reduced susceptibility to ESCs and azithromycin with
sufficient sensitivity and specificity, suggesting the impor-
tance of additional (perhaps combinatorial) markers.
The dataset analysed in the present study is publicly avail-
able as a BioProject deposited in DDBJ/NCBI (Table S1). To
our knowledge, this is the largest dataset that consists of
both raw read sequences and MIC values in response to
ESCs, fluoroquinolone and macrolides of more than 200
strains sampled in a single geographical region. We expect
that the dataset will be a valuable resource for future studies,
in particular for exploring additional markers for resistance.
Furthermore, by combining the dataset with that of the his-
torical gonococcal strains within Japan, we were able to
reveal the different evolutionary paths of the two major line-
ages that have been spreading worldwide that likely origi-
nated in Japan [64]. The ST7363-associated lineage evolved
from a susceptible ancestor that acquired penA X, and
underwent recombination between penA X and penA V in
the sub-lineage. By contrast, the evolution of the ST1901-
associated lineage was more complicated: although the
ancestral susceptible penA allele was the same as that of the
ST7363-associated lineage, penA X and XXXIV were
acquired independently on different ancestral lineages. Our
study provides a solid basis for the further elucidation of the
origin and evolution of the two major lineages that are
spreading worldwide.
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